NCT05004974View on ClinicalTrials.gov

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 30, 2025

Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DRUG

Sintilimab

Sintilimab is administered every 3 weeks (200mg, IV).

DRUG

Pemigatinib

Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.

Trial Locations (1)

310000

RECRUITING

The Fourth Affiliated Hospital of Zhejiang University, Yiwu

All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER